news aktuell GmbHnews aktuell GmbH

BrainRepair UG: Investment breakthrough for BrainRepair UG start-up – Stem cell treatment for newborns

Share
Dr. Metin Colpan, founder of Nasdaq listed Qiagen N.V. acquired 5% of BrainRepair UG shares worth EUR 15M

(Bochum, Germany): One of the most successful inventors and entrepreneurs who masterminded the unprecedented success of Qiagen N.V. from a start-up to a 10 billion market cap enterprise has taken the decision to refocus his activities on BrainRepair UG, a spin-off of the Ruhr-University Bochum (RUB). BrainRepair UG has developed a unique method based on own (autologous) cord blood stem cells to treat brain damage and cerebral palsy (CP) in newborns affecting 70,000 babies in the EU each year. Metin Colpan’s patented invention has become a standard method recommended by the World Health Organization (WHO) and is used by researchers all over the world, changing the way they can access, purify and understand genetic data in DNA and RNA. The European Patent Office states “…The tireless work of German scientist Metin Colpan over four decades has paved the way for rapid and effective genetic data analysis, enabling researchers to better detect disease and unlocking new therapies for conditions, including COVID-19,” and Prof. Dr. Arne Jensen, Co-Founder and CEO of BrainRepair UG, continues “We are delighted that we now can draw on the vast experience Dr. Colpan is offering us as Member of the Board of Directors and Chairman of the Advisory Board on our way to the stock market at Nasdaq First North for which the IPO is planned in November 2021.” BrainRepair UG’s stem cell product has been granted the worldwide first ‘Orphan Drug Designation’ (ODD) by the European Commission and the European Medicines Agency. This designation guarantees market exclusivity in all EU member states for 12 years upon market authorisation. Prof. Arne Jensen stresses, “All our personal, scientific, clinical, and philanthropic efforts serve the ultimate goal – to combat infantile Cerebral palsy, the most common disability in childhood, and stop CP in children!”

About Qiagen N.V.
QIAGEN is a German provider of sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research. Consolidated under the Dutch holding QIAGEN N.V., the company operates more than 35 offices in over 25 countries.[16] QIAGEN's shares are listed at the NYSE (using ticker QGEN) and at the Frankfurt Stock Exchange in the Prime Standard (using ticker QIA). Thierry Bernard is the company's Chief Executive Officer. The main operative headquarters are located in Hilden, Germany. Number of employees: about 5,000. Total equity: US $2,634.970 million. Industry: Biotechnology. Total assets: US $5,748.332 million. Market capitalization: US $ 11,123 billion.

About BrainRepair UG
BrainRepair UG is a clinical stage start-up developing cutting edge stem cell treatments based on human cord blood for a wide range of indications related to brain injury in children including those caused by oxygen lack and inflammation (PVL, HIE, NE), hemorrhage, stroke, cerebral palsy (CP), traumatic brain injury (TBI), and spinal cord injury (SCI). BrainRepair UG is the first Biotech company worldwide whose stem cell products have been awarded ‘Orphan Medicinal Product Designations’ for the treatment of brain injury in newborn infants (PVL, NE) by the European Commission and the European Medicines Agency, EMA. BrainRepair’s Headquarter is in Bochum, Germany. You may visit the website at https://brainrepair.eu/ for more information.

Links:
Metin Colpan (DE) - Finalist for the European Inventor Award 2021 – EPO https://www.epo.org/news-events/events/european-inventor/finalists/2021/colpan.html

Autologous Cord Blood Therapy for Infantile Cerebral Palsy: From Bench to Bedside,Obstet Gynecol Int vol.2014,12p; https://www.hindawi.com/journals/ogi/2014/976321/

First Autologous Cord Blood Therapy for Pediatric Ischemic Stroke and Cerebral Palsy Caused by Cephalic Molding during Birth: Individual Treatment with Mononuclear Cells", Case Reports in Transplantation, vol. 2016, Article ID 1717426, 9 pages, 2016. https://www.hindawi.com/journals/crit/2016/1717426/

EMA Orphan medicinal Product Designation Periventricular leukomalacia (PVL): https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3161744

EMA Orphan medicinal Product Designation Newborn encephalopathy (NE): https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3161743

Contacts

BrainRepair UG (haftungsbeschränkt)
Prof. Dr. med. Arne Jensen, MD, MBA
Ruhr-University Bochum
Campus Clinic Gynaecology
Universitätsstr. 136
44799 Bochum, Germany
Tel.: +49 234 588 196-0
Fax.: +49 234 588 196-19
Email: arne.jensen@brainrepair.eu

Images

Dr. Metin Coplan, Founder and long-term CEO of Qiagen N.V. and Finalist of the EPO European Inventor Award 2021
Dr. Metin Coplan, Founder and long-term CEO of Qiagen N.V. and Finalist of the EPO European Inventor Award 2021
Download

About news aktuell GmbH

news aktuell GmbH
news aktuell GmbH
Mittelweg 144
20148 Hamburg

+49 (0)40 4113-32589http://www.newsaktuell.de

news aktuell, a subsidiary of the Deutsche Presse-Agentur (dpa), provides companies, institutions and associations with effective access to both the media and consumers and supports the organizations in telling their stories easily and successfully. Utilizing the digital tools “ots” and “zimpel” PR content reaches all media formats, including classic print titles, wide-reach online portals or social networks. In addition, news aktuell publishes all of its clients' PR content on www.presseportal.de, one of Germany's widest-reaching PR portals. Thus, all relevant multipliers are reached worldwide, ranging from editors and digital influencers to specialist bloggers and interested consumers. Communications specialists from all over Germany rely on the expertise of the dpa subsidiary. news aktuell has been on the market since 1989 and employs over 135 people. The company is based in Hamburg. Further locations include Berlin, Frankfurt and Munich.

Subscribe to releases from news aktuell GmbH

Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from news aktuell GmbH

EUROJET signs contract to provide EJ200 Engines for the recent Italian Air Force Eurofighter Order of up to 24 Aircraft27.6.2025 16:25:57 CEST | Press release

Rome, Italy, Friday, 27th June 2025 EUROJET Turbo GmbH, the consortium behind the EJ200 engine that powers the Eurofighter Typhoon, has today signed a new contract with the NATO Eurofighter & Tornado Management Agency (NETMA). Under this agreement, EUROJET will deliver up to 54 new EJ200 engines to the Italian Air Force as part of the Eurofighter Tranche I replacement. A renaissance of interest in the programme, it follows hot on the heels of the Spanish Halcón II contract announced at the end of last year.

Invest Taicang: The 17th Taicang Day in Stuttgart Celebrates Over 30 Years of Sino-German Cooperation and Innovation26.6.2025 08:41:11 CEST | Press release

On June 25, the 17th "Taicang Day" event kicked off in Stuttgart, marking a significant milestone in the longstanding relationship between Taicang, a city in E China, and Germany. The event returned to its original location in the heart of the "Motor City," where nearly 300 guests, including officials from the Baden-Württemberg state government, the Ministry of Economic Affairs, the Stuttgart government, the German Chamber of Commerce, renowned trade and investment promotion organizations, and executives from German companies, gathered to discuss new opportunities for Sino-German cooperation. Hosted by the Taicang municipal government, this year's theme, "Innovation-Driven, Green Win-Win," highlighted Taicang's deepening ties with Germany across various sectors, including trade, education, culture, and sustainability. The event was a platform for fostering continued collaboration between both nations, with key discussions on shared innovation and sustainable development. In his opening

EMD's Retail Group further consolidates its position with Axfood from Sweden / The international retail alliance EMD is continuing to expand its importance in the cooperation with the A-brand industry25.6.2025 08:30:00 CEST | Pressemelding

Pfäffikon/Switzerland, 13/06/2025: By effectively combining forces to benefit its millions of retail customers, European Marketing Distribution (EMD) has risen to the top of the international trade alliances with this formula. The latest example of this successful strategy is the integration of the Swedish Axfood Group, an EMD member since 1995, which will join the EMD Retail Group in 2026. To clarify: while EMD and its member companies focus on the procurement and marketing of successful private label products, EMD members united in the Retail Group also implement cross-border services and marketing concepts in partnership with leading multinational A-brand manufacturers.

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye